Depomed (DEPO) Active, Shares Gain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street shares close up as megacap tech stocks rally
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil settles higher on supply concerns in the Mideast, economic woes subdue gains
- 'This is Enron:' Facebook and Asana co-founder accuses Tesla of 'massive' fraud
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Midday movers: Alphabet, Microsoft and Snap rise; Intel, Hertz Global fall
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
Janney Montgomery Scott Reiterates Buy as Court Rules in Favor of Depomed (DEPO)
October 3, 2016 7:55 AM EDTJanney Montgomery Scott reiterated a Buy rating on DepoMed Inc (NASDAQ: DEPO), and raised the price target to $31.00 (from $28.00), following a court ruling in favor of the company. The Court issued an Order in favor of DEPO in its patent litigation against and secures Nucynta through... More
Depomed (DEPO) to Resume Trading at 4;20 PM ET
September 30, 2016 4:07 PM EDTDepomed (NASDAQ: DEPO) to Resume Trading at 4;20 PM ET
... MoreDepomed (DEPO) Announces Favorable Ruling on NUCYNTA Providing Market Exclusivity Until December 2025
September 30, 2016 3:56 PM EDTDepomed, Inc. (Nasdaq: DEPO) today announced that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation against all three filers of Abbreviated New Drug Applications (ANDAs) for Depomed's NUCYNTA franchise. With the courts ruling, Depomed expects market... More
Depomed (DEPO) Wins Order Obtaining Injunction vs. Defendants Over Generic Nucynta (AGN)
September 30, 2016 3:19 PM EDTDepomed (Nasdaq: DEPO) wins order obtaining injunction blocking generic version of Nucynta, according to Bloomberg.
Allergan (NYSE: AGN) can't sell generic Nucynta pending final judgment. Actavis, Roxane also lost an effort to invalidate Nucynta patents.
Depomed's patents on Nucynta expire between 2022 and 2028.
... MoreDepomed (DEPO) Halted, News Pending
September 30, 2016 3:17 PM EDTDepomed (NASDAQ: DEPO) Halted, News Pending
... More
